Resources & Tools
References
- The Asthma Control Test. Available at: http://www.asthmacontroltest.com/ (last accessed April 2019).
- 2019 GINA Report. Available at: http://ginasthma.org/ (last accessed May 2019).
- Relvar Ellipta SmPC, available on www.medicines.ie (Last accessed, April 2019).
RELVAR Ellipta was developed in collaboration with INNOVIVA Inc.

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse events can also be reported to the HPRA by calling: (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
© 2019 GlaxoSmithKline Group of Companies. Relvar and Ellipta are trademarks of the GSK group of companies.
Relvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:
- patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short acting beta2-agonists
- patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist.